89Strontium in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes.

Hematological and biochemical parameters were evaluated in 31 patients receiving 150 MBq 89Strontium (89Sr) intravenously due to painful skeletal metastases from hormone resistant prostate cancer. Two and 3 months after the injection prostate specific antigen (PSA) had increased by a median of 36% a...

Descripción completa

Detalles Bibliográficos
Autores principales: Fosså, S. D., Paus, E., Lochoff, M., Backe, S. M., Aas, M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1992
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977884/
https://www.ncbi.nlm.nih.gov/pubmed/1379058
_version_ 1782135358075437056
author Fosså, S. D.
Paus, E.
Lochoff, M.
Backe, S. M.
Aas, M.
author_facet Fosså, S. D.
Paus, E.
Lochoff, M.
Backe, S. M.
Aas, M.
author_sort Fosså, S. D.
collection PubMed
description Hematological and biochemical parameters were evaluated in 31 patients receiving 150 MBq 89Strontium (89Sr) intravenously due to painful skeletal metastases from hormone resistant prostate cancer. Two and 3 months after the injection prostate specific antigen (PSA) had increased by a median of 36% and 100%, respectively, as compared to the pretreatment value whereas alkaline phosphatase (APHOS) had decreased by about 20% (median). The leucocyte and platelet counts were reduced by about 20-35%, without reaching grade greater than or equal to 2 toxicity. Pain relief was reported in 14 of 29 evaluable patients at 2 months and in 11 of 23 patients at 3 months. It is concluded that 89Sr represents a worthwhile therapeutic modality in the palliation treatment of patients with hormone resistant prostate cancer, though the biological significance of frequently increasing PSA and decreasing APHOS is not yet completely understood. IMAGES:
format Text
id pubmed-1977884
institution National Center for Biotechnology Information
language English
publishDate 1992
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19778842009-09-10 89Strontium in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes. Fosså, S. D. Paus, E. Lochoff, M. Backe, S. M. Aas, M. Br J Cancer Research Article Hematological and biochemical parameters were evaluated in 31 patients receiving 150 MBq 89Strontium (89Sr) intravenously due to painful skeletal metastases from hormone resistant prostate cancer. Two and 3 months after the injection prostate specific antigen (PSA) had increased by a median of 36% and 100%, respectively, as compared to the pretreatment value whereas alkaline phosphatase (APHOS) had decreased by about 20% (median). The leucocyte and platelet counts were reduced by about 20-35%, without reaching grade greater than or equal to 2 toxicity. Pain relief was reported in 14 of 29 evaluable patients at 2 months and in 11 of 23 patients at 3 months. It is concluded that 89Sr represents a worthwhile therapeutic modality in the palliation treatment of patients with hormone resistant prostate cancer, though the biological significance of frequently increasing PSA and decreasing APHOS is not yet completely understood. IMAGES: Nature Publishing Group 1992-07 /pmc/articles/PMC1977884/ /pubmed/1379058 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Fosså, S. D.
Paus, E.
Lochoff, M.
Backe, S. M.
Aas, M.
89Strontium in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes.
title 89Strontium in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes.
title_full 89Strontium in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes.
title_fullStr 89Strontium in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes.
title_full_unstemmed 89Strontium in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes.
title_short 89Strontium in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes.
title_sort 89strontium in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977884/
https://www.ncbi.nlm.nih.gov/pubmed/1379058
work_keys_str_mv AT fossasd 89strontiuminbonemetastasesfromhormoneresistantprostatecancerpalliationeffectandbiochemicalchanges
AT pause 89strontiuminbonemetastasesfromhormoneresistantprostatecancerpalliationeffectandbiochemicalchanges
AT lochoffm 89strontiuminbonemetastasesfromhormoneresistantprostatecancerpalliationeffectandbiochemicalchanges
AT backesm 89strontiuminbonemetastasesfromhormoneresistantprostatecancerpalliationeffectandbiochemicalchanges
AT aasm 89strontiuminbonemetastasesfromhormoneresistantprostatecancerpalliationeffectandbiochemicalchanges

Ejemplares similares